Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results
August 2, 2018 8:00 AM EDT-- EXPAREL® net product sales of $80.4 million up 15% over prior year second quarter ---- Full-year EXPAREL net product sales guidance increased to $320 to $325 million ---- Conference Call Today at 8:30 a.m. ET --
PARSIPPANY, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the second quarter ended June 30, 2018.
The first half of 2018 was marked by tremendous progress as our EXPAREL growth strategy is taking hold and driving robust topline results, said Dave Stack, chairman and chief executive... More
